Amylyx Pharmaceuticals, Inc. (AMLX) Tops Q1 EPS by 29c

Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) reported Q1 EPS of $0.02, $0.29 better than the analyst estimate of ($0.27). Revenue for the quarter came in at $71.43 million versus the consensus estimate of $58.32 million.

For earnings history and earnings-related data on Amylyx Pharmaceuticals, Inc. (AMLX) click here.

You May Also Be Interested In

• Amylyx Pharmaceuticals inc. (AMLX) PT Raised to $40 at Guggenheim
• UBS Downgrades Grand Korea Leisure (114090:KS) to Neutral
• Hyperscale Data acquires 48.5 acres to expand Michigan campus